Tuesday, December 18, 2018 5:27:19 PM
Single agent Copiktra (duvelisib) induced robust, durable responses in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who experienced disease progression after treatment with Arzerra (ofatumumab).
BY KRISTIE L. KAHL
PUBLISHED DECEMBER 18, 2018
Single agent Copiktra (duvelisib) induced robust, durable responses in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who experienced disease progression after treatment with Arzerra (ofatumumab) alone, according to data from the DUO crossover extension study.
In the phase 3 study, patients treated with Copiktra demonstrated a significant improvement in progression-free survival – or the time to disease progression or worsening – compared with those treated with Arzerra (median, 13.3 months vs. 9.9 months). In addition, the agent showed a manageable safety profile.
“This (trial) led to the (Food and Drug Administration) approval of the drug back in September,” study author Matthew S. Davids, M.D., MMSc, noted in an interview with CURE.
In this open-label, optional, crossover extension study – presented at the 2018 American Society of Hematology (ASH) Annual Meeting – Davids reported on data for the 90 patients who crossed over following disease progression on Arzerra and went on to receive 25 mg of Copiktra twice daily until disease progression, intolerance, death, or study withdrawal.
Median age was 68 years, and the majority of patients were male (63 percent) and white (90 percent). Patients received a median of three therapies prior to Copiktra, with 60 percent who were given three or more prior anticancer therapies.
The median progression-free survival after patients crossed over to Copiktra was 15 months, compared with nine months before patients crossed over. Of note, this was significant among those with a 17p deletion (17 months vs. eight months, respectively).
Similarly, overall response rates were higher in patients after treatment crossover compared with before (77 percent vs. 29 percent), and again in the 17p deletion subset (80 percent vs. 15 percent).
Forty-seven patients experienced no response prior to crossover. The overall response rate in this group was 73 percent after treatment with Copiktra.
Patients treated with Copiktra achieved rapid lymphocytosis (median, 1.1 months) with a median time to first response of 2.6 months.
The most common severe hematologic side effects with Copiktra included neutropenia (23 percent) and thrombocytopenia (4 percent). The most common severe non-hematologic side effects were diarrhea (21 percent), pneumonia (12 percent), colitis (11 percent), lipase increased (7 percent), acute renal failure (6 percent), and bronchitis, rash and sepsis (4 percent, each).
About 70 percent of patients had dose modifications due to side effects, most commonly from diarrhea (27 percent), pneumonia (10 percent), colitis (8 percent), neutropenia and lipase increased (7 percent each). Events of colitis (10 percent), diarrhea (9 percent), pneumonia (2 percent) and rash (2 percent) led to treatment discontinuation.
“(Copiktra) is an effective treatment option for patients with relapsed CLL after two or more lines of therapy,” said Davids, who is the associate director of the Center for Chronic Lymphocytic Leukemia at Dana Farber Cancer Institute in Boston. “Patients may receive other lines of therapy like (Arzerra) and then go on to get (Copiktra) and still do very well. So, I think even though we have many therapeutic options in CLL, it is always important to have new options, and I think this is a good one for our CLL patients.”
https://www.curetoday.com/articles/crossover-study-offers-additional-line-of-therapy-for-patients-with-relapsed-cllsll
Recent VSTM News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/18/2024 08:30:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/18/2024 08:30:17 PM
- Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference • Business Wire • 09/10/2024 08:05:00 PM
- Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting • Business Wire • 09/10/2024 11:30:00 AM
- Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024 • Business Wire • 09/03/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:10:42 PM
- Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates • Business Wire • 08/08/2024 08:05:00 PM
- Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer • Business Wire • 07/29/2024 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/25/2024 12:45:23 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/24/2024 09:06:01 PM
- Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants • Business Wire • 07/24/2024 03:20:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/23/2024 08:33:23 PM
- Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants • Business Wire • 07/23/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/23/2024 08:01:17 PM
- Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet Therapeutics • Business Wire • 07/12/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 11:00:18 AM
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 07/08/2024 11:30:00 AM
- Verastem Oncology Announces Addition to Russell 3000® and Russell Microcap® Indexes • Business Wire • 07/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 11:01:58 AM
- Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer • Business Wire • 05/24/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 09:24:02 PM
- Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer • Business Wire • 05/23/2024 09:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:08:56 PM
- Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates • Business Wire • 05/09/2024 08:02:00 PM
- Verastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference • Business Wire • 05/07/2024 11:30:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM